	Approved for use through 7/31/2003. OMB 0651-0031 U.S. Patent and Trade Office; U.S. DEPARTMENT OF COMMERCE				
Under the Paperwork Reduction Act of unless it displays a valid OMB control number.					
REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14					
RECEIVED	In re Application of				
Bring completed form to: File Information Unit Crystal Plaza Three, Room 1001 MAR 1 4 2005	Application Number Filed Filed Pec_20_1991				
2021 South Clark Place Arlington, VA Telephone: (703) 308-2733	Paper No.#35				
I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):					
United States Patent Application Publication No, page,line					
United States Patent Number 5266683, column, line, or					
WIPO Pub. No, page	_, line				
Related Information about Access to Pendin Direct access to pending applications is not available to purchased from the Office of Public Records upon paymer For published applications that are still pending, a member the file contents; the pending application as originally filed; or any document in the file of the pending application. For unpublished applications that are still pending: (1) If the benefit of the pending application is claimed us application that has: (a) issued as a U.S. patent, or (contents).	of the appropriate fee (37 CFR 1.19(b)), as follows: er of the public may obtain a copy of:				

patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

the file contents;

the pending application as originally filed; or

any document in the file of the pending application.

(2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

the pending application as originally filed.

Signature 0 SALIAB GILAYOUN
Typed or printed name

FOR PTO USE ONLY

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the obstation) to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gainering, preparing, and submitting the completed application form to the OSPTO. Time will vary depending upon the individual case. Any comments of the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1001, 2021 South Clark Place, Arlington, VA.



Patent Number:

5,266,683

Date of Patent: *Nov. 30, 1993

Oppermann et al.

[75] Inventors: Hermann Oppermann, Medway;

United States Patent [19]

Engin Ozkaynak, Milford; Thangavel Kuberasampath, Medway; David C. Rueger, Hopkinton; Roy H. L. Pang,

Medway, all of Mass.

[73] Assignee: Stryker Corporation, Kalamazoo,

Mich.

[*] Notice: The portion of the term of this patent

subsequent to Nov. 2, 2010 has been

disclaimed.

[21] Appl. No.: 841,646

[22] Filed: Feb. 21, 1992

Related U.S. Application Data

Continuation-in-part of Ser. No. 827,052, Jan. 28, 1992, Pat. No. 5,250,302, Ser. No. 579,865, Oct. 7, 1990, Pat. No. 5,108,753, Ser. No. 621,849, Dec. 4, 1990, abandoned, Ser. No. 621,988, Dec. 4, 1990, abandoned, Ser. No. 810,560, Dec. 20, 1991, abandoned, Ser. No. 569,920, Aug. 20, 1990, abandoned, Ser. No. 600,024, Oct. 18, 1990, abandoned, Ser. No. 599,543, Oct. 18, 1990, abandoned, Ser. No. 616,374, Nov. 21, 1990, Pat. No. 5,162,114, and Ser. No. 483,913, Feb. 22, 1990, Pat. No. 5,171,574, said Ser. No. 827,052, is a division of Ser. No. 179,406, Apr. 8, 1988, Pat. No. 4,968,590, said Ser. No. 579,865, is a division of Ser. No. 179,406, Apr. 8, 1988, said Ser. No. 621,849, is a division of Ser. No. 232,630, Aug. 15, 1988, abandoned, which is a continuation-in-part of Ser. No. 179,406, Aug. 15, 1988, said Ser. No. 621,988, is a division of Ser. No. 315,342, Feb. 23, 1989, Pat. No. 5,011,691, which is a continuation-in-part of Ser. No. 232,630, Feb. 23, 1989, said Ser. No. 810,560, is a continuation of Ser. No. 660,162, Feb. 22, 1991, abandoned, which is a continuation of Ser. No. 422,699, Oct. 17, 1989, abandoned, which is a continuation-in-part of Ser. No. 315,342, Oct. 17, 1989, said Ser. No. 569,920, is a continuation-in-part of Ser. No. 422,699, Oct. 17, 1989, and Ser. No. 483,913, Oct. 17, 1989, which is a continuation-in-part of Ser. No. 422,613, Oct. 17, 1989, Pat. No. 4,975,526, which is a continuation-in-part of Ser. No. 315,342, Oct. 17, 1989, said Ser. No. 600,024, is a continuation-in-part of Ser. No. 569,920, Oct. 17, 1989, said Ser. No. 599,543, is a continuation-in-part of Ser. No. 569,920, Oct. 17, 1989.

[51]	Int. Cl.	5	A61K 37/0	2; C07K 5/00; 0; C07K 15/00
[52]	U.S. CI		530	/326; 530/327;
[58]	Field of		0/328; 530/350; 530 530/326, 530	
[56]		Re	ferences Cited	
U.S. PATENT DOCUMENTS				
4	,172,128	10/1979	Thiele et al	424/95
4	,294,753	10/1981	Urist	530/356
4	,394,370	7/1983	Jefferies	424/15
4	,434,094	2/1984	Seyedin et al	
	.455.256		Urist	
4	.563,350	1/1986	Nathan et al	
4	,563,489	1/1986	Urist	524/21
(List continued on next page.)				

FOREIGN PATENT DOCUMENTS

069260 6/1982 European Pat. Off. . (List continued on next page.)

OTHER PUBLICATIONS

Canalis et al., Science 210:1021-1023 (1980). Glowacki et al., Lancet 1:959-963 (1981). Reddi, Collagen Rel. Res. 1:209-226 (1981). Sampath et al. Proc. Natl. Acad. Sci. USA 78:7599-7603 (1981).

(List continued on next page.)

Primary Examiner-Nathan M. Nutter Attorney, Agent, or Firm-Testa, Hurwitz & Thibeault

ABSTRACT

Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors carrying sequences encoding these novel polypeptide chains and host cells transfected with these vectors; (4) methods of producing these polypeptide chains using recombinant DNA technology; (5) antibodies specific for these novel polypeptide chains; (6) osteogenic devices comprising these recombinantly produced proteins in association with an appropriate carrier matrix; and (7) methods of using the osteogenic devices to mimic the natural course of endochondral bone formation in mam-

58 Claims, 47 Drawing Sheets